<DOC>
	<DOCNO>NCT01575691</DOCNO>
	<brief_summary>5-aza chemotherapy drug activity leukemia myelodysplastic syndrome ( MDS ) . Researchers hope valproic acid ( VPA ) all-trans retinoic acid ( ATRA ) increase effect 5-aza . The goal clinical research study find high safe dose valproic acid ( VPA ) give combination 5-azacytidine ( 5-aza ) all-trans retinoic acid ( ATRA ) treatment AML MDS . The safety effectiveness combination therapy also study .</brief_summary>
	<brief_title>Phase I 5-Azacytidine Plus VPA Plus ATRA</brief_title>
	<detailed_description>Participants receive 5-aza injection skin day 7 day . This repeated every 3-8 week depend blood count well bone marrow recover . This define 1 treatment cycle . Also cycle , participant take VPA mouth 7 day ATRA mouth 5 day . VPA give day 5-aza . ATRA start Day 3 . In Phase I portion study , dose VPA increase new group participant high safe dose find . A minimum 3 participant maximum 10 treat dose level .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>Patients refractory relapse : acute myelogenous leukemia ( AML ) , myelodysplastic syndrome ( MDS ) ( bone marrow blast &gt; = 10 % ) eligible . Untreated patient old 60 year age AML MDS ( bone marrow blast &gt; = 10 % ) refuse eligible frontline chemotherapy , eligible . Performance status &lt; = 2 Eastern Cooperative Oncology Group ( ECOG ) scale . Signed informed consent indicate patient aware investigational nature study keep policy University Texas M D Anderson Cancer Center ( UTMDACC ) . Age &gt; 2 year . Valproic acid associate high rate severe liver toxicity child young 2 year . Patients must chemotherapy 2 week prior enter study recover toxic effect therapy , unless evidence rapidly progressive disease . Use hydroxyurea patient rapidly proliferative disease allow first two week therapy . Adequate liver function ( bilirubin &lt; 2mg/dL , SGPT &lt; 3 * Upper Limits Normal ( ULN ) ) renal function ( creatinine &lt; 2mg/dL ) . Women childbearing potential must practice contraception . Men woman must continue birth control duration trial . Patients relapse /refractory disease inv16 , ( 8 ; 21 ) ( 15 ; 17 ) eligible . Nursing pregnant female exclude . Patients active uncontrolled infection exclude . Patients already receive valproic acid receive anticonvulsant exclude . Untreated patient young 60 year candidate study . Patients untreated disease inv16 , ( 8 ; 21 ) ( 15 ; 17 ) exclude .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Combination Chemotherapy</keyword>
	<keyword>MDS</keyword>
	<keyword>High-Risk Myelodysplastic Syndrome</keyword>
	<keyword>AML</keyword>
	<keyword>Acute myelogenous leukemia</keyword>
	<keyword>valproic acid</keyword>
	<keyword>VPA</keyword>
	<keyword>Depakene</keyword>
	<keyword>5-azacytidine</keyword>
	<keyword>5-aza</keyword>
	<keyword>Azacitidine</keyword>
	<keyword>5-AZC</keyword>
	<keyword>Vidaza</keyword>
	<keyword>AZA-CR</keyword>
	<keyword>Ladakamycin</keyword>
	<keyword>NSC-102816</keyword>
	<keyword>All-trans retinoic acid</keyword>
	<keyword>ATRA</keyword>
	<keyword>Tretinoin</keyword>
	<keyword>Vesanoid</keyword>
</DOC>